Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Vandana Singh
1 min read
0

  • Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. (NYSE: MRK) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors.

  • The investigator-initiated trial at UPMC is an open-label, Phase 1/1b study consisting of two parts.

  • Part I is a dose escalation study of four cohorts and is expected to enroll 18-30 patients.

  • Part 2 is a dose expansion study of approximately 40 patients to evaluate the safety and tolerability of the recommended combination dose of I/ONTAK and pembrolizumab.

  • Related: Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm.

  • The study will also investigate the alteration of the immune microenvironment within tumors and peripheral blood.

  • Secondary endpoints include the objective response (complete response plus partial response), progression-free survival, and overall survival.

  • University of Pittsburgh dose-ranging study is expected to begin in the fourth quarter of 2022.

  • Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN).

  • This Phase 1 dose-finding study to evaluate I/ONTAK before Novartis AG's (NYSE: NVS) Kymriah (tisagenleucel) CAR-T therapy for diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.

  • Price Action: CTXR shares closed 6.84% higher at $1.25 during after-hours trading on Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories